While the technology sector has been enjoying ridiculous returns, it's inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks. This is just as inno
Jazz's (JAZZ) fourth-quarter earnings miss estimates while sales meet the mark. Shares drop 1.5% post the announcement.
Jazz Pharmaceuticals PLC (JAZZ) Q4 2023 Earnings Call Transcript
The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimate
Jazz Pharmaceuticals (JAZZ) came out with quarterly earnings of $5.02 per share, missing the Zacks Consensus Estimate of $5.26 per share. This compares to loss of $0.07 per share a year ago.
While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.
Besides Wall Street's top -and-bottom-line estimates for Jazz (JAZZ), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quart
While many top cannabis stocks have existed for years, the U.S. market has warmed up to the cannabinoid sector only recently. About 40 states allow the use of cannabis, although not all permit its rec
DUBLIN , Feb. 14, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2023 full year and fourth quarter financial results on Wednesday, February 28, 20
JAZZ inks a deal to acquire global rights to Redx Pharma's KRAS inhibitor program to strengthen its early-stage oncology pipeline.

3 Biotech Stocks to Buy on the Dip: February 2024

07:35am, Wednesday, 07'th Feb 2024
Biotech investing is not for impatient investors. So why is it attractive to some investors?
Redx Pharma PLC (AIM:REDX) said it is sellling its KRAS inhibitor programme to Nasdaq-listed Jazz Pharma Inc in a deal with a headlne value of $880 million. Under the terms of the transaction, Redx w
There is a lot of good news to digest from the biotech sector. Not only does it offer lots of strong stocks in January, but it is also expected to grow rapidly.
Jazz Pharmaceuticals is likely to fall short of its 2025 revenue goal of $5 billion unless it makes a bold M&A move. Despite this, the stock looks undervalued and has the potential to re-rate higher,
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) received an Outperform rating and a target price of $160 from Baird, citing optimistic expectations for the company's performance in the coming year. Initiating
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE